Loading...

Takara Bio

DB:TF2
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TF2
DB
¥285B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan and internationally. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
TF2 Share Price and Events
7 Day Returns
-3%
DB:TF2
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
21.4%
DB:TF2
-10.2%
DE Biotechs
-6%
DE Market
TF2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Takara Bio (TF2) -3% -11.6% -9.5% 21.4% 47.9% 131.6%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • TF2 outperformed the Biotechs industry which returned -10.2% over the past year.
  • TF2 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
TF2
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Takara Bio's competitors could be found in our database.

Value

 Is Takara Bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Takara Bio to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Takara Bio.

DB:TF2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:TF2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 30.86%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:TF2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Takara Bio is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:TF2 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 7.98%)
2019 4,070.00 Analyst x1 3,769.36
2020 2,449.00 Analyst x2 2,100.56
2021 5,853.33 Analyst x3 4,649.69
2022 6,996.50 Analyst x2 5,147.24
2023 9,337.00 Analyst x2 6,361.72
2024 11,756.00 Analyst x2 7,418.23
2025 13,647.63 Est @ 16.09% 7,975.74
2026 15,194.16 Est @ 11.33% 8,223.64
2027 16,409.81 Est @ 8% 8,225.54
2028 17,340.06 Est @ 5.67% 8,049.80
Present value of next 10 years cash flows ¥61,921.52
DB:TF2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ¥17,340.06 × (1 + 0.23%) ÷ (7.98% – 0.23%)
¥224,315.54
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥224,315.54 ÷ (1 + 7.98%)10
¥104,134.26
DB:TF2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥61,921.52 + ¥104,134.26
¥166,055.78
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥166,055.78 / 120.42
¥1379.02
DB:TF2 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:TF2 represents 0.00775x of TSE:4974
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.00775x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 1,379.02 x 0.00775
€10.69
Value per share (EUR) From above. €10.69
Current discount Discount to share price of €18.34
= -1 x (€18.34 - €10.69) / €10.69
-71.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Takara Bio is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Takara Bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Takara Bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:TF2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥27.86
TSE:4974 Share Price ** TSE (2019-04-18) in JPY ¥2367
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Takara Bio.

DB:TF2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4974 Share Price ÷ EPS (both in JPY)

= 2367 ÷ 27.86

84.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Takara Bio is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Takara Bio is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Takara Bio's expected growth come at a high price?
Raw Data
DB:TF2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 84.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
22.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:TF2 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 84.95x ÷ 22.2%

3.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Takara Bio is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Takara Bio's assets?
Raw Data
DB:TF2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥523.96
TSE:4974 Share Price * TSE (2019-04-18) in JPY ¥2367
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:TF2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4974 Share Price ÷ Book Value per Share (both in JPY)

= 2367 ÷ 523.96

4.52x

* Primary Listing of Takara Bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Takara Bio is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Takara Bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Takara Bio has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Takara Bio expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Takara Bio expected to grow at an attractive rate?
  • Takara Bio's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Takara Bio's earnings growth is expected to exceed the Germany market average.
  • Takara Bio's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:TF2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:TF2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 22.2%
DB:TF2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 10%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:TF2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:TF2 Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 58,376 12,288 10,391 2
2023-03-31 53,142 10,298 8,943 3
2022-03-31 45,887 9,092 7,071 3
2021-03-31 41,382 7,982 6,085 3
2020-03-31 37,152 7,320 4,417 3
2019-03-31 36,707 5,358 3,315 3
DB:TF2 Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 35,554 7,495 3,355
2018-09-30 35,556 7,238 3,753
2018-06-30 34,804 6,970 3,345
2018-03-31 32,312 3,935 2,335
2017-12-31 31,376 2,683 859
2017-09-30 30,302 2,146 987
2017-06-30 29,424 2,198 1,089
2017-03-31 29,375 3,584 1,352
2016-12-31 29,668 3,142 2,282
2016-09-30 29,671 3,931 1,856
2016-06-30 30,274 3,525 1,655
2016-03-31 29,729 3,021 1,334

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Takara Bio's earnings are expected to grow significantly at over 20% yearly.
  • Takara Bio's revenue is expected to grow by 10% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:TF2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Takara Bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TF2 Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31 86.30 86.30 86.30 1.00
2023-03-31 72.60 77.00 65.60 3.00
2022-03-31 59.30 61.50 56.10 3.00
2021-03-31 49.52 55.60 45.48 4.00
2020-03-31 34.40 39.12 27.49 4.00
2019-03-31 27.86 28.48 27.40 3.00
DB:TF2 Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 27.86
2018-09-30 31.17
2018-06-30 27.78
2018-03-31 19.39
2017-12-31 7.13
2017-09-30 8.20
2017-06-30 9.04
2017-03-31 11.23
2016-12-31 18.95
2016-09-30 15.41
2016-06-30 13.74
2016-03-31 11.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Takara Bio is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Takara Bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Takara Bio has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Takara Bio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Takara Bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Takara Bio's year on year earnings growth rate has been positive over the past 5 years.
  • Takara Bio's 1-year earnings growth exceeds its 5-year average (290.6% vs 19.5%)
  • Takara Bio's earnings growth has exceeded the Europe Biotechs industry average in the past year (290.6% vs 18.2%).
Earnings and Revenue History
Takara Bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Takara Bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TF2 Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 35,554.00 3,355.00 10,919.00 4,400.00
2018-09-30 35,556.00 3,753.00 10,779.00 4,460.00
2018-06-30 34,804.00 3,345.00 10,504.00 4,564.00
2018-03-31 32,312.00 2,335.00 10,446.00 4,653.00
2017-12-31 31,376.00 859.00 10,499.00 4,648.00
2017-09-30 30,302.00 987.00 10,052.00 4,494.00
2017-06-30 29,424.00 1,089.00 10,068.00 4,254.00
2017-03-31 29,375.00 1,352.00 9,648.00 4,101.00
2016-12-31 29,668.00 2,282.00 9,394.00 4,027.00
2016-09-30 29,671.00 1,856.00 9,545.00 4,096.00
2016-06-30 30,274.00 1,655.00 9,460.00 4,205.00
2016-03-31 29,729.00 1,334.00 9,380.00 4,275.00
2015-12-31 29,382.00 1,660.00 9,063.00 4,294.00
2015-09-30 28,255.00 704.00 8,671.00 4,082.00
2015-06-30 26,951.00 909.00 8,325.00 3,718.00
2015-03-31 25,969.00 963.00 8,123.00 3,401.00
2014-12-31 25,031.00 844.00 7,975.00 3,097.00
2014-09-30 24,599.00 1,647.00 7,863.00 3,021.00
2014-06-30 24,514.00 1,742.00 7,721.00 3,025.00
2014-03-31 23,905.00 1,470.00 7,593.00 3,026.00
2013-12-31 22,815.00 1,291.00 7,240.00 2,876.00
2013-09-30 21,828.00 1,375.00 7,034.00 2,812.00
2013-06-30 20,630.00 1,103.00 6,747.00 2,773.00
2013-03-31 20,564.00 1,462.00 6,617.00 2,715.00
2012-12-31 20,051.00 1,238.00 6,500.00 2,755.00
2012-09-30 19,949.00 1,114.00 6,367.00 2,710.00
2012-06-30 19,859.00 1,154.00 6,313.00 2,696.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Takara Bio has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Takara Bio used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Takara Bio has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Takara Bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Takara Bio has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Takara Bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Takara Bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Takara Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Takara Bio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Takara Bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Takara Bio has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Takara Bio Company Filings, last reported 3 months ago.

DB:TF2 Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 63,192.00 0.00 20,183.00
2018-09-30 62,266.00 0.00 21,111.00
2018-06-30 60,921.00 0.00 20,689.00
2018-03-31 61,957.00 0.00 19,537.00
2017-12-31 60,314.00 115.00 16,775.00
2017-09-30 59,137.00 650.00 17,294.00
2017-06-30 58,750.00 643.00 16,667.00
2017-03-31 59,984.00 129.00 30,078.00
2016-12-31 58,411.00 163.00 27,817.00
2016-09-30 57,773.00 163.00 28,692.00
2016-06-30 59,084.00 187.00 29,424.00
2016-03-31 60,109.00 193.00 29,105.00
2015-12-31 59,688.00 211.00 27,839.00
2015-09-30 59,823.00 211.00 27,956.00
2015-06-30 59,288.00 225.00 24,086.00
2015-03-31 59,642.00 236.00 23,883.00
2014-12-31 57,350.00 353.00 27,404.00
2014-09-30 56,686.00 348.00 29,111.00
2014-06-30 56,497.00 361.00 30,690.00
2014-03-31 57,127.00 364.00 29,933.00
2013-12-31 55,034.00 337.00 25,679.00
2013-09-30 54,762.00 332.00 32,086.00
2013-06-30 42,324.00 359.00 20,231.00
2013-03-31 41,465.00 356.00 20,785.00
2012-12-31 39,176.00 385.00 19,570.00
2012-09-30 38,784.00 375.00 20,660.00
2012-06-30 39,050.00 396.00 20,643.00
  • Takara Bio has no debt.
  • Takara Bio has no debt compared to 5 years ago when it was 0.6%.
  • Takara Bio has no debt, it does not need to be covered by operating cash flow.
  • Takara Bio has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Takara Bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Takara Bio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Takara Bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.3%
Current annual income from Takara Bio dividends. Estimated to be 0.4% next year.
If you bought €2,000 of Takara Bio shares you are expected to receive €6 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Takara Bio's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.43%).
  • Takara Bio's dividend is below the markets top 25% of dividend payers in Germany (3.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:TF2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:TF2 Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2024-03-31 14.00 1.00
2023-03-31 13.00 2.00
2022-03-31 11.00 2.00
2021-03-31 8.40 5.00
2020-03-31 7.25 4.00
2019-03-31 7.00 3.00
DB:TF2 Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-02-08 7.000 0.279
2019-02-06 7.000 0.298
2018-06-28 6.000 0.228
2018-05-11 6.000 0.243
2017-06-29 4.000 0.241
2017-05-09 4.000 0.260
2016-06-29 1.800 0.119
2016-05-09 1.800 0.129
2015-11-06 1.500 0.124
2015-08-07 1.500 0.126
2015-06-23 1.500 0.110
2015-05-22 1.500 0.108
2014-06-27 1.200 0.083
2014-05-08 1.200 0.092
2013-06-27 1.100 0.057
2013-05-09 1.100 0.038
2012-07-27 1.000 0.138
2012-06-28 1.000 0.246
2012-05-09 1.000 0.253
2012-01-30 1.000 0.216

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Takara Bio is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Takara Bio is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Takara Bio's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Takara Bio's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • No need to calculate the sustainability of Takara Bio's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Takara Bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Takara Bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Takara Bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Takara Bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Koichi Nakao
AGE 56
CEO Bio

Mr. Koichi Nakao has been the President of Takara Bio Inc. since May 2009 and serves as its Chief Executive Officer. Mr. Nakao served as the Chief Operating Officer of Takara Bio Inc. He serves as the Chairman of Takara Korea Biomedical Inc. Mr. Nakao has been a Director of Takara Bio Inc. since April 2002 and Takara Holdings Inc., since June 2009. He serves as Managing Director at Takara Bio Inc. since June 2003. He serves as Senior Managing Director at Takara Bio Inc. since June 2004. He serves as Executive Vice President at Takara Bio Inc. since June 2007. He serves as President at Takara Bio USA Holdings Inc. (incumbent) since May 2009.

CEO Compensation
  • Insufficient data for Koichi to compare compensation growth.
  • Insufficient data for Koichi to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Takara Bio management team in years:

4.8
Average Tenure
62
Average Age
  • The tenure for the Takara Bio management team is about average.
Management Team

Hisashi Ohmiya

TITLE
Chairman of the Board
AGE
75

Koichi Nakao

TITLE
CEO, President & Representative Director
AGE
56

Carol Lou

TITLE
President

Junichi Mineno

TITLE
MD, Senior Executive Officer & Director
TENURE
4.8 yrs

Shuichiro Matsuzaki

TITLE
Executive VP & Director
AGE
62
TENURE
4.8 yrs

Andrew Farmer

TITLE
Head of Research and Development

Yoh Hamaoka

TITLE
Senior Executive Officer

Tsuyoshi Miyamura

TITLE
Senior Executive Officer & Director

Masahide Tamaki

TITLE
Senior Executive Officer
TENURE
2.8 yrs

Kazuki Yamamoto

TITLE
Senior Executive Officer
Board of Directors Tenure

Average tenure and age of the Takara Bio board of directors in years:

4.3
Average Tenure
63
Average Age
  • The tenure for the Takara Bio board of directors is about average.
Board of Directors

Hisashi Ohmiya

TITLE
Chairman of the Board
AGE
75
TENURE
17 yrs

Koichi Nakao

TITLE
CEO, President & Representative Director
AGE
56
TENURE
3.8 yrs

Junichi Mineno

TITLE
MD, Senior Executive Officer & Director
TENURE
4.8 yrs

Shuichiro Matsuzaki

TITLE
Executive VP & Director
AGE
62
TENURE
4.8 yrs

Tsuyoshi Miyamura

TITLE
Senior Executive Officer & Director
TENURE
0.8 yrs

Masanobu Kimura

TITLE
Senior Executive Officer & Director
TENURE
1.8 yrs

Jawaharlal Bhatt

TITLE
External Director
TENURE
8.8 yrs

Nobuko Kawashima

TITLE
External Director
TENURE
2.8 yrs

Kiyozo Asada

TITLE
Standing Audit & Supervisory Board Member
AGE
64
TENURE
7.8 yrs

Akihiko Kita

TITLE
Standing Audit & Supervisory Board Member
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Takara Bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Takara Bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan and internationally. It operates through Bioindustry, Gene Therapy, and AgriBio segments. The company develops original research reagents and scientific instruments; and provides contracted services that utilize new genetic engineering and cell engineering technologies on consistent basis, which support life sciences field that range from basic research to drug discovery and development. Its contracted services include development of virus vectors and cells for gene transduction based on good gene, cellular and tissue-based product manufacturing practices, and good manufacturing practices; quality and safety testing services; and production and storage of cell banks. The company also provides a package of regenerative medicine development and genetic testing support services, such as genetic analysis. In addition, it engages in the development and commercialization of various gene therapies, including oncolytic virus Canerpaturev for strain of the herpes simplex virus, which exhibits antitumor activity when inserted into a cancerous region; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of esophageal cancer, synovial sarcoma, and other cancers; and CD19 chimeric antigen receptors gene therapy for the treatment of adult acute lymphocytic leukemia. Further, the company provides functional foods, such as Gagome kombu (kelp) fucoidan, Peucedanum japonicum-derived isosamidin, Dioscorea esculenta-derived Yamsgenin, and mushroom products. Additionally, it produces various mushroom types, such as Honshimeji, Hatakeshimeji, and Bunashimeji. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Details
Name: Takara Bio Inc.
TF2
Exchange: DB
Founded: 2002
¥2,264,299,977
120,415,600
Website: http://www.takara-bio.com
Address: Takara Bio Inc.
Nojihigashi 7-4-38,
Kusatsu,
Shiga, 525-0058,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4974 Common Stock The Tokyo Stock Exchange JP JPY 07. Dec 2004
DB TF2 Common Stock Deutsche Boerse AG DE EUR 07. Dec 2004
Number of employees
Current staff
Staff numbers
1,448
Takara Bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 20:38
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/05
Last earnings filing: 2019/02/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.